Evidence map›Paper›PMID 24186004›Full record

Trial reportLeukemia2014

Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients.

U Platzbecker, H K Al-Ali, N Gattermann, D Haase, V Janzen, J Krauter, K Götze, R Schlenk, F Nolte, A Letsch and 11 more

Abstract readClinical Trial, Phase IILetter
PubMed Publisher
In one paragraph

Trial report in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Targeting EZH2 for cancer therapy: progress and perspective.Current protein & peptide science · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

U PlatzbeckerUniversitätsklinikum Dresden, Dresden, Germany.
H K Al-AliUniversitätsklinikum Leipzig, Leipzig, Germany.
N GattermannUniversitätsklinikum Düsseldorf, Düsseldorf, Germany.
D HaaseUniversitätsmedizin Göttingen, Göttingen, Germany.
V JanzenUniversitätsklinikum Bonn, Bonn, Germany.
J KrauterMedizinische Hochschule Hannover, Hannover, Germany.
K GötzeKlinikum rechts der Isar der Technischen Universität München, München, Germany.
R SchlenkUniversitätsklinikum Ulm, Ulm, Germany.
F NolteUniversitätsmedizin Mannheim, Mannheim, Germany.
A LetschCharité Berlin, Berlin, Germany.
O G OttmannUniversitätsklinikum Frankfurt, Frankfurt, Germany.
A KündgenUniversitätsklinikum Düsseldorf, Düsseldorf, Germany.
M LübbertUniversitätsklinikum Freiburg, Freiburg, Germany.
U GermingUniversitätsklinikum Düsseldorf, Düsseldorf, Germany.
M WermkeUniversitätsklinikum Dresden, Dresden, Germany.
H ReinhardNovartis Pharma GmbH Nürnberg, Nürnberg, Germany.
C WeissNovartis Pharma GmbH Nürnberg, Nürnberg, Germany.
K LiederNovartis Pharma GmbH Nürnberg, Nürnberg, Germany.
G EhningerUniversitätsklinikum Dresden, Dresden, Germany.
O LeismannNovartis Pharma GmbH Nürnberg, Nürnberg, Germany.
A GiagounidisMarienhospital Düsseldorf, Düsseldorf, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Blood TransfusionAdministration, OralErythropoietinHumansHydroxamic AcidsIndolesMyelodysplastic SyndromesPanobinostatErythropoietinHydroxamic AcidsIndolesPanobinostat

Identifiers

PMID24186004

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.